AUTL 8-K: SEC filing

Autolus Therapeutics plc

Filed with the SEC on Nov 10, 2026 · accession 0001730463-26-000141

AUTL filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Autolus Therapeutics plc announced its financial results for the quarter ended September 30, 2026 and provided a corporate update via press release and corporate presentation.

For details, click here →How to read a 8-K →

Key details

RegistrantAutolus Therapeutics plc

Chief executive officerChristian Itin, Ph.D.

✦ Ask GOAX AI about this filing — what it means for AUTL, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for AUTL?

Click here

Frequently asked questions

What did AUTL file with the SEC on Nov 10, 2026?

AUTL filed a 8-K (SEC filing). Autolus Therapeutics plc announced its financial results for the quarter ended September 30, 2026 and provided a corporate update via press release and corporate presentation.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other AUTL SEC filings

Get alerts when AUTL files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

AUTL overview AUTL analysis AUTL news Latest SEC filings